CWM
DNLI icon

CIBC World Markets’s Denali Therapeutics DNLI Stock Holding History

CIBC World Markets’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$228K Sell
16,318
-11,264
-41% -$159K ﹤0.01% 1219
2025
Q1 		$375K Buy
27,582
+15,949
+137% +$306K ﹤0.01% 1143
2024
Q4 		$237K Buy
+11,633
New +$298K ﹤0.01% 1045

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

CIBC World Markets's DNLI Position: Q2 2025 in Review

CIBC World Markets reduced its Denali Therapeutics (DNLI) stake by 41% in Q2 2025, selling an estimated $159K and leaving 16,318 shares worth $228K. The position accounts for ﹤0.01% of the portfolio, ranked #1219.

CIBC World Markets first reported a position in DNLI in Q4 2024 and has held it in 3 quarters since. The position peaked at $375K in Q1 2025. 230 funds tracked by Wall St. Rank hold DNLI as of Q2 2025.

  • CIBC World Markets held 16,318 shares of Denali Therapeutics worth $228K as of Q2 2025.
  • CIBC World Markets sold 11,264 Denali Therapeutics shares in Q2 2025, an estimated $159K.
  • Denali Therapeutics made up ﹤0.01% of CIBC World Markets's portfolio in Q2 2025, its #1219 holding.
  • CIBC World Markets first reported a position in Denali Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • CIBC World Markets's Denali Therapeutics position peaked at $375K in Q1 2025.
  • 230 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2025.

Based on CIBC World Markets's 13F filing for Q2 2025, filed 14 Aug 2025.